NLBNPIT20W12 20240920 48 (P20W12) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of...

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program PR Newswire STOCKHOLM, May 23, 2024...

Form 8-K - Current report

Tango Therapeutics Announces Discontinuation of TNG348 Program

– The phase 1/2 clinical trial of TNG348, a USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts – – Cash...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

– Dose expansion initiated in TNG908 phase 1/2 clinical trial – – Dose expansion expected to initiate in TNG462 phase 1/2 clinical trial in 2Q...

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of...

Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights

– Dose escalation ongoing in four clinical-stage precision oncology programs; TNG908 phase 1/2 clinical data expected in 2024 – – First patient...

Tango Therapeutics to Participate in Upcoming Investor Conferences

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of...

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024

BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage...